“We are excited to introduce the Mix-n-Stain™ CF® Dye IgM Antibody Labeling Kits to the scientific community,” says Dr. Lori Roberts, Director of Bioscience at Biotium. “This technology provides a new and simple solution to the longstanding challenge of IgM conjugation. We believe these kits will provide researchers with more flexibility in panel design for immunofluorescence and flow cytometry.”

Dr. Jeremy Skillington, Chief Executive Officer of Poolbeg, commented: “The validation of the encapsulation process is a key step in the creation of a Phase I clinical trial ready oral vaccine candidate and Poolbeg is proud to lead the EncOVac Consortium. Delivering oral vaccines to the gut has the potential to revolutionise global protection against infectious disease. In contrast to intramuscular vaccines that generate systemic immunity, oral vaccines induce mucosal immunity, which can induce better protection against pathogens at the site of infection.”

AntiBKV has potential to be first- and best-in-class treatment representing the sole option for large and growing number of patients. Interim data expected by the end of 2023; on track to reach patients in 2025.

After identifying common antibodies unique to individuals resilient to Alzheimer’s disease, Alchemab identified the target as CD33. By starting with the body’s response to disease, as opposed to the target itself, Alchemab’s platform inverts the traditional ‘target-led’ drug discovery process. In effect, the immune system is used as a search function to identify the most important disease modifying targets.

This proposed change in Valneva’s governance structure will be submitted to the vote of the Company’s shareholders at an Extraordinary General Meeting later this year.